Showing results (71-80 of 218) with videos related to
Sort By:
Pageof 22
Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.Journal of the National Cancer Institute|January 2, 2017
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + IpilimumabClaire F Friedman, Varina Clark, Andrew V Raikhel, et al.Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2020
Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitorsN Shaverdian, J Beattie, M Thor, et al.European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.Nature|November 14, 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyMarta Łuksza, Nadeem Riaz, Vladimir Makarov, et al.Advances in Radiation Oncology|September 12, 2018
Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibitionDonata von Reibnitz, Jamie E Chaft, Abraham J Wu, et al.Nature|May 18, 2017
Chromatin states define tumour-specific T cell dysfunction and reprogrammingMary Philip, Lauren Fairchild, Liping Sun, et al.ESMO Open|June 27, 2018
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)Filippo de Marinis, Fortunato Ciardiello, Paul Baas, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2023
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen PresentationCharles M Rudin, David Balli, W Victoria Lai, et al.Pageof 22